Literature DB >> 1512248

Purification and characterization of dihydropyrimidine dehydrogenase from human liver.

Z H Lu1, R Zhang, R B Diasio.   

Abstract

Although dihydropyrimidine dehydrogenase has been purified to varying degrees from several species, very little is known about the human enzyme. The importance of this enzyme has recently been shown with cancer chemotherapy, particularly in patients with genetic deficiency of this enzyme. In the present study, this enzyme was purified 7800-fold to homogeneity from human liver by introducing several novel methods including chromatofocusing, HPLC gel filtration, reversed-phase HPLC for the enzyme assay. Purified human enzyme has a molecular mass of 210 +/- 5 kDa and appears to be composed of two subunits. The apparent pI is pH 4.6 (+/- 0.2). The human enzyme contains approximately four flavin nucleotide molecules (two each of FAD and FMN) and 33 iron atoms per molecule of enzyme. Kinetic studies with uracil, thymine, 5-fluorouracil, and NADPH were carried out. Amino acid composition and the N-terminal amino acid sequence of this enzyme were reported. A rabbit polyclonal antibody was raised and shown to be specific for the human liver enzyme. In conclusion, in the present manuscript, we report not only a novel procedure for purification of dihydropyrimidine dehydrogenase from human liver but also new data on its properties compared to other species, which will provide a basis for further biochemical and molecular studies of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1512248

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Differential expression of uridine phosphorylase in tumors contributes to an improved fluoropyrimidine therapeutic activity.

Authors:  Deliang Cao; Amy Ziemba; James McCabe; Ruilan Yan; Laxiang Wan; Bradford Kim; Michael Gach; Stuart Flynn; Giuseppe Pizzorno
Journal:  Mol Cancer Ther       Date:  2011-09-27       Impact factor: 6.261

Review 2.  TAS-102, a novel antitumor agent: a review of the mechanism of action.

Authors:  Heinz-Josef Lenz; Sebastian Stintzing; Fotios Loupakis
Journal:  Cancer Treat Rev       Date:  2015-06-06       Impact factor: 12.111

3.  Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in gallbladder carcinoma.

Authors:  Shuichi Iwahashi; Mitsuo Shimada; Tohru Utsunomiya; Yuji Morine; Satoru Imura; Tetsuya Ikemoto; Hiroki Mori; Jun Hanaoka
Journal:  Surg Today       Date:  2012-01-24       Impact factor: 2.549

4.  Quantitative Contribution of rs75017182 to Dihydropyrimidine Dehydrogenase mRNA Splicing and Enzyme Activity.

Authors:  Q Nie; S Shrestha; E E Tapper; C S Trogstad-Isaacson; K J Bouchonville; A M Lee; R Wu; C R Jerde; Z Wang; P A Kubica; S M Offer; R B Diasio
Journal:  Clin Pharmacol Ther       Date:  2017-05-26       Impact factor: 6.875

Review 5.  Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines.

Authors:  R B Diasio
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy.

Authors:  Yu Abe; Naoki Sakuyama; Tsuyoshi Sato; Kenji Kishine; Kiichi Nagayasu; Akinori Nakatani; Masayuki Kitajima; Tomoo Watanabe; Kazuhiko Nishimura; Takumi Ochiai; Isao Nagaoka
Journal:  Mol Clin Oncol       Date:  2019-07-03

7.  Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase.

Authors:  R B Diasio
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

8.  DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.

Authors:  M Wasif Saif; Kostas Syrigos; Ranee Mehra; Lori K Mattison; Robert B Diasio
Journal:  Pak J Med Sci       Date:  2007       Impact factor: 1.088

Review 9.  Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy.

Authors:  Liming Weng; Li Zhang; Yan Peng; R Stephanie Huang
Journal:  Pharmacogenomics       Date:  2013-02       Impact factor: 2.533

10.  Blood-brain barrier efflux transport of pyrimidine nucleosides and nucleobases in the rat.

Authors:  Zoran B Redzic; Slava A Malatiali; James D Craik; Miodrag L Rakic; Aleksandra J Isakovic
Journal:  Neurochem Res       Date:  2008-08-27       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.